Clinical Trial Update: Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 [Phase 3]

View source ↗

Summary

A Phase 3 study comparing RTH258 (brolucizumab) to aflibercept in neovascular age-related macular degeneration focuses on efficacy and safety. Results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• RTH258 (brolucizumab)

Snippet

Sponsor: Alcon Research | Conditions: Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Status: COMPLETED | Results posted: 2019-10-31